Evidence map›Paper›PMID 40235610›Full record

ArticleFocus (American Psychiatric Publishing)2025

Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.

Sophie I Elliott, Rachel B Katz, Robert B Ostroff, Mina Ansari, Sophie E Holmes, Gerard Sanacora

Abstract read
In one paragraph

Article in Focus (American Psychiatric Publishing), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sophie I ElliottDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (all authors); Interventional Psychiatry Services, Yale Psychiatry Hospital, New Haven, Connecticut (Katz, Ostroff, Ansari, Holmes, Sanacora).
Rachel B KatzDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (all authors); Interventional Psychiatry Services, Yale Psychiatry Hospital, New Haven, Connecticut (Katz, Ostroff, Ansari, Holmes, Sanacora).
Robert B OstroffDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (all authors); Interventional Psychiatry Services, Yale Psychiatry Hospital, New Haven, Connecticut (Katz, Ostroff, Ansari, Holmes, Sanacora).
Mina AnsariDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (all authors); Interventional Psychiatry Services, Yale Psychiatry Hospital, New Haven, Connecticut (Katz, Ostroff, Ansari, Holmes, Sanacora).
Sophie E HolmesDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (all authors); Interventional Psychiatry Services, Yale Psychiatry Hospital, New Haven, Connecticut (Katz, Ostroff, Ansari, Holmes, Sanacora).
Gerard SanacoraDepartment of Psychiatry, Yale University School of Medicine, New Haven, Connecticut (all authors); Interventional Psychiatry Services, Yale Psychiatry Hospital, New Haven, Connecticut (Katz, Ostroff, Ansari, Holmes, Sanacora).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effective treatment of major depressive disorder remains one of the biggest public health challenges globally. For moderate to severe cases, pharmacotherapy often falls short, leading to treatment-resistant depression. Electroconvulsive therapy (ECT) has generally been considered the gold standard for severe cases of treatment-resistant depression. However, emerging evidence suggests that ketamine may serve as a promising alternative. Two relatively large noninferiority trials and three meta-analyses support the efficacy of both treatments but report contradictory findings regarding superiority. The authors discuss possible reasons underlying these discrepant findings, including variations in patient selection criteria, study outcome measures, treatment delivery, and site experience. Additionally, the authors examine the unique risk and benefit profiles of each treatment, highlighting patient-specific considerations. By evaluating the most recent evidence for the efficacy of ketamine versus ECT alongside key patient-specific factors, the authors aimed to guide clinicians in recommending the optimal treatment choice for each patient.

Indexed as

Electroconvulsive TherapyKetamineMajor Depressive DisorderPatient-CenteredTreatment-Resistant Depression

Identifiers

PMID40235610
PMCPMC11995899

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.